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Abstract
Background: Maternal obesity and pre-pregnancy diabetes mellitus, features of the metabolic
syndrome (MetSyn), are individual risk factors for neural tube defects (NTD). Whether they, in
combination with additional features of MetSyn, alter this risk is not known. We evaluated the risk
of NTD in association with maternal features of the MetSyn.
Methods: We used a population-based case-control study design in the province of Ontario,
Canada. Cases and controls were derived from women who underwent antenatal maternal
screening (MSS) at 15 to 20 weeks' gestation. There were 89 maternal cases with, and 434 controls
without, an NTD-affected singleton pregnancy. Maternal features of MetSyn were defined by the
presence of pre-pregnancy diabetes mellitus, body weight ≥ 90th centile among controls, non-white
ethnicity and/or serum highly sensitive C-reactive protein (hsCRP) ≥ 75th centile of controls. Since
hsCRP naturally increases in pregnancy, analyses were performed with, and without, the inclusion
of hsCRP in the model.
Results: Mean hsCRP concentrations were exceptionally high among study cases and controls (6.1
and 6.4 mg/L, respectively). When hsCRP was excluded from the model, the adjusted odds ratios
for NTD were 1.9 (95% confidence interval 1.1–3.4) in the presence 1 feature of MetSyn, and 6.1
(1.1–32.9) in the presence of 2 or more features. When hsCRP was included, the respective risk
estimates were attenuated to 1.6 (0.88–2.8) and 3.1 (1.2–8.3).
Conclusion: We found about 2-fold and 6-fold higher risk for NTD in the presence 1, and 2 or
more features, of the metabolic syndrome, respectively. It is not clear whether this risk is altered
by the presence of a high serum hsCRP concentration.
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Background
The risk of neural tube defects (NTD) – spina bifida and
anencephaly – is significantly reduced by a periconcep-
tional intake of folic acid [1]. While a large proportion of
NTD may be preventable, risk factors for NTD that are
independent of folate metabolism, including maternal
obesity [2] and pre-pregnancy diabetes mellitus (DM)
may persist [3].
The metabolic syndrome (MetSyn) is characterized by a
cluster of metabolic risk factors including abdominal
obesity, DM or insulin resistance, non-white ethnicity [4],
dyslipidemia, chronic hypertension and elevated inflam-
matory highly sensitive serum C-reactive protein (hsCRP)
[5]. Since 40% of Western teenagers exhibit a sedentary
lifestyle [6] and 5–16% are obese [6,7], MetSyn is now
seen in 15% of women who are in their reproductive years
[8].
If obesity and pre-pregnancy DM are each independent
risk factors for NTD, then it is valuable to know how they
interact together, and with other features of MetSyn,
namely, non-white ethnicity and elevated serum hsCRP.
We examined whether these selected features of MetSyn
are additively associated with an increased risk of NTD.
Methods
We performed a population-based case-control study.
Details of the study methods are described elsewhere
[9,10]. Briefly, since 1993, standardized maternal serum
screening (MSS) was made available to all women at 15 to
20 weeks' gestation through a physician or midwife, with
a mean rate of use of more than 60%. The current study
comprised the period from 1994 to late 2000. Self-
declared maternal date of birth, gravidity, ethnicity, cur-
rent weight, and the presence of prepregnancy DM were
recorded in a standardized fashion on the MSS Requisi-
tion Sheet, completed by the caregiver at the time of
screening. Open NTD cases were detected antenatally by
ultrasonography or fetal autopsy, or postnatally through
data linkage of the mother's Ontario health insurance
number with that of her infant during the delivery hospi-
talization, through the Canadian Institute for Health
Information Discharge Abstract Database [9,10].
For each case, five maternal controls without an NTD-
affected pregnancy were randomly selected within a +/-
24-month period. Serum samples, originally collected at
the time of MSS in the index singleton pregnancy, were
frozen at -70°C. Each frozen sample was thawed and ana-
lyzed for hsCRP using the DPC Immulite 2000 immu-
noassay analyzer (Diagnostic Products Corporation, Los
Angeles, CA), whose functional sensitivity is 0.2 mg/L,
with within- and between-run CVs of 2.8 % and 3.1 % at
3.2 mg/L, and 3.4 % and 3.8 % at 21.8 mg/L, respectively.
Serum folate was analyzed using the Bayer Centaur immu-
noassay analyzer method (Bayer Diagnostics Division,
Toronto, ON). The distribution of serum hsCRP and
folate values was positively skewed, so we log-trans-
formed these measures and used inverse transformations
to generate geometric means and standard deviations
(SD).
Statistical analysis
Maternal characteristics were compared between groups
using a non-paired t-test for continuous variables, a
median or Wilcoxon rank-sum test for non-parametric
data, and the chi-square test or Fisher's exact test for cate-
gorical data.
Maternal MetSyn features were defined as follows: 1) pres-
ence of pre-pregnancy DM; 2) weight ≥ 90th centile value
of the controls; 3) non-white ethnicity; and 4) serum
hsCRP ≥ 75th centile value in controls.
Crude and adjusted odds ratios (OR) and 95% confidence
intervals (CI) were derived using unconditional logistic
regression analysis, comparing women with 0, 1 or ≥ 2
features of MetSyn, with 0 features as the referent. We
adjusted for maternal age (1-year increments) and serum
folate concentration at the time of MSS, as well as the
prevalence of low-income status within each participant's
neighborhood. The latter was defined as less than the low-
income cut-off for all Ontarians [10]. The forward sorta-
tion area of each participant (i.e., the first three characters
of her postal code) was used to identify each woman's
neighborhood, from the 2001 Canadian Census. The
trend in the risk of NTD according to the number of fea-
tures of the MetSyn was evaluated using a Cochran-Armit-
age test for trend.
Since hsCRP increases in pregnancy, distinguishing an
abnormal from a physiologically elevated value is difficult
[11], so the above modeling was performed with and
without the inclusion of hsCRP.
Means and SD were computed and compared using an
unpaired t-test. All variables were included in the model a
priori, and statistical significance was set at a 2-sided p <
0.05. Analyses were performed using SAS Version 8.0 (SAS
Institute, Cary, NC). The study was done in accordance
with a research protocol approved through the Ministry of
Health and Longterm Care in Ontario, and approval of
the Research Ethics Boards of St. Michael's Hospital and
The North York General Hospital, with all participant
identifiers removed prior to analysis.
Results
We included 89 NTD-affected pregnancies and 434 unaf-
fected pregnant controls (Table 1). All cases had a mini-BMC Pregnancy and Childbirth 2007, 7:21 http://www.biomedcentral.com/1471-2393/7/21
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mum of four controls available, and the majority had five.
About half (263) of all participants were from the pre-
folic acid fortification era and 260 were from the period
after. Of all 89 NTD cases, 67 (75.3%) were diagnosed
antenatally.
Mean serum hsCRP were 6.1 and 6.4 mg/L in the cases
and controls, respectively (Table 1). When hsCRP was
excluded from the model, the crude OR for NTD were 1.9
(1.2–3.1) and 6.1 (1.2–30.9) in the presence 1 and 2 or
more features of MetSyn, respectively, relative to none
(trend p = 0.001) (Table 2). The corresponding adjusted
OR were essentially the same (Table 2). With hsCRP
included as a feature of MetSyn, the adjusted OR for NTD
was 1.6 (0.88–2.8) in the presence of 1 feature, and 3.1
(1.2–8.3) in the presence of at least 2 features, relative to
none (trend p = 0.009) (Table 2).
In a post hoc analysis that excluded both hsCRP and eth-
nicity from the models, the crude OR were 1.5 (0.84–2.7)
and 1.4 (0.70–2.8) for 1 and 2 or more features of the
Table 2: Risk of open neural tube defects in relation to certain maternal features of the metabolic syndrome (MetSyn)
Prevalence of MetSyn Odds ratio (95% CI)
Model No. features of 
MetSyn
No. (%) 
cases
No. (%) 
controls
Crude Adjusted** P-value for trend
Without hsCRP as 
a feature of 
MetSyn
0 (n = 382) 54 (60.7) 328 (75.6) 1.0 (ref) 1.0 (ref) 0.001
1 (n = 135) 32 (36.0) 103 (23.7) 1.9 (1.2–3.1) 1.9 (1.1–3.4)
≥ 2 (n = 6) 3 (3.4) 3 (0.69) 6.1 (1.2–30.9) 6.1 (1.1–32.9)
With hsCRP as a 
feature of 
MetSyn*
0 (n = 351) 50 (56.2) 301 (69.4) 1.0 (ref) 1.0 (ref) 0.009
1 (n = 147) 32 (36.0) 115 (26.5) 1.7 (1.0–2.7) 1.6 (0.88–2.8)
≥ 2 (n = 25) 7 (7.8) 18 (4.1) 2.3 (0.93–5.9) 3.1 (1.2–8.3)
*Not all participants had a serum sample available for hsCRP evaluation
**Adjusted for maternal age (1-year increments), serum folate concentration and low income status.
hsCRP highly-sensitive C-reactive protein; CI confidence interval
Table 1: Participant characteristics
Maternal characteristic Cases of women with an NTD-
affected pregnancy (n = 89)
Controls of women without an NTD-
affected pregnancy (n = 434)
P-value, comparing 
cases and controls
Mean (SD) age, years 28.6 (4.8) 29.8 (5.1) 0.04
Median gravidity 2.0 2.0 0.02
Weight, kg
Mean (SD) 68.6 (15.5) 67.4 (13.5) 0.50
90th centile 87.6 83.9* 0.50
No. (%) with prepregnancy 
diabetes mellitus
3 (3.4) 5 (1.2) 0.14
Ethnicity (No. [%])
White 56 (70.9) 367 (85.8) 0.01
Asian 16 (20.2) 41 (9.6)
Black 5 (6.3) 12 (2.8)
Other 2 (2.5) 8 (1.9)
Mean (SD) % with low income 
status in the local population
12.9 (6.7) 13.2 (7.5) 0.77
Geometric mean (SD) serum 
folate, nmol/L
13.3 (3.0) 13.9 (2.8) 0.96
Serum highly sensitive C-
reactive protein, mg/L
Geometric mean (SD) 6.1 (2.9) 6.4 (2.3) 0.92
75th centile 13.0 11.5* --
*Used to define the abnormal cut-point in the current study.BMC Pregnancy and Childbirth 2007, 7:21 http://www.biomedcentral.com/1471-2393/7/21
Page 4 of 5
(page number not for citation purposes)
MetSyn, respectively. The corresponding adjusted OR
were 1.4 (0.70–2.8) and 1.5 (0.40–5.7).
Discussion
In the presence of at least one feature of MetSyn in preg-
nancy, the risk of NTD was nearly doubled. In the pres-
ence of two or more features, it was six times higher.
Inclusion of hsCRP as a MetSyn feature attenuated these
risk estimates considerably.
Our study was limited by the manner in which the fea-
tures of MetSyn were determined. Its retrospective design
enabled us to assess only a sub-set of these features, and
neither chronic hypertension nor dyslipidemia [5] were
included herein. While we evaluated self-reported mater-
nal weight, this was not paired with height, nor was it
measured before pregnancy. However, there appears to be
little variation between self-reported and measured
weight in pregnancy [12,13]. Furthermore, maternal
weight and body mass index (BMI) are highly correlated
[14,15], as are second trimester and pre-pregnancy BMI
[16]. Our inclusion of women with pre-pregnancy DM
did not distinguish between those with type 1 and type 2
DM, nor did our use of broad ethnic categories enable us
to account for the additional within-group diversity,
including country of birth. Nonetheless, others have
emphasized the utility of "non-white" ethnicity as a deter-
minant of risk for MetSyn [8,17,18]. We previously
observed that women of First Nations ancestry had about
a five times higher risk of NTD compared to White
women, which was not so among women of other non-
White ethnic origins [19]. Finally, it was not known how
many cases or controls were taking folic acid tablet sup-
plements periconceptionally, a major determinant of
NTD risk [1], although we did adjust for serum folate sta-
tus at the time of screening, as well as socioeconomic sta-
tus, which itself is a predictor of periconceptional folic
acid supplement use [20].
Including hsCRP as a feature of MetSyn attenuated the risk
of NTD in this study. A likely explanation is the physiolog-
ical effect of pregnancy on hsCRP [11]. This was reflected
by an exceptionally high mean hsCRP concentrations
among cases and controls [21], which likely diminished
our ability to detect any association, if truly present.
Recent evidence from the Framingham Offspring Study
suggests that combining hsCRP in a model of MetSyn
does not improve the ability to predict cardiovascular dis-
ease risk [21]. Clearly, measuring hsCRP prior to concep-
tion, or months after completion of pregnancy, would
better a better test of its utility for predicting NTD risk.
Which features of MetSyn best predict the risk of NTD?
Shaw and colleagues found that both a high-caloric diet
[22] and a sedentary lifestyle [23] were independent risk
factors for NTD. In their Californian population-based
case-control study, the risk of NTD was highest among
women who mean dietary glycemic index was in the
upper vs. lower quartile (adjusted OR 1.9, 95% CI 1.3–
2.7), especially when periconceptional BMI was also ele-
vated (adjusted OR 4.0, 95% CI 1.0–15.7) [22]. Other
studies, including ours, have confirmed the likely role of
maternal obesity and DM as risk factors for NTD [2,3].
While it may be worthwhile to include both hypertriglyc-
eridemia and chronic hypertension in a MetSyn model of
NTD risk, they too are better measured in the non-preg-
nant state, as they are altered by pregnancy [24]. Chronic
hypertension could conceivably alter the risk of NTD
based on the link to maternal hyperhomocysteinemia
[25], but it is possible that there are other biologically
plausible explanations.
Fewer than 10% of maternal cases studied herein exhib-
ited two or more features of MetSyn. Nonetheless, because
MetSyn is now so prevalent among adults and children
[7,8], this figure likely has importance at both the individ-
ual and societal levels. Most features of MetSyn can be
inexpensively determined within an outpatient clinical
setting, including measurement of BMI or pre-pregnancy
waist circumference, blood pressure and capillary blood
glucose concentration. We suggest that women consider-
ing pregnancy who are at risk for MetSyn be advised to
increase dietary and supplemental intakes of folic acid,
and consider a path of healthy eating and regular physical
activity. More evidence is needed to determine whether
maternal "metabolic modification" [26] can safely and
efficaciously lower the risk of NTD.
Conclusion
These preliminary findings suggest that there is a higher
associated risk of NTD in the presence of features of the
MetSyn. It is not clear whether this risk is altered by the
additional presence of a high serum hsCRP concentration.
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